Promega and Roche wait for verdict in their patent dispute over the taq enzyme
This article was originally published in Clinica
Promega's patent battle with Roche over the taq enzyme used in the polymerase chain reaction (PCR) process will be decided in the autumn. The trial ended last week with Madison, Wisconsin-based Promega confident that its argument had persuaded the federal district judge in a San Francisco court that Roche's US patent was obtained by fraud.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.